Compared side by side

Retatrutide vs BPC-157: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

They do different jobs: retatrutide is a weekly agonist of three receptors, GLP-1, GIP and glucagon, run for weight loss, and BPC-157 is a peptide derived from a protein in human gastric juice that, in animal studies, protects the gut lining and speeds tendon, ligament and muscle repair. Retatrutide’s top dose averaged about 25–28% weight loss at 80 weeks in phase 3, and it isn’t approved yet; BPC-157’s human studies so far are three small uncontrolled pilots. Commonly reported: GI side effects after each retatrutide step-up, and a calmer gut on BPC-157, which the library lists beside retatrutide for GI support.

Side by side

ComparedRetatrutideBPC-157
CategoryMetabolic & GLP-1Healing & recovery
Also known asLY3437943Body Protection Compound 157, BPC157
What it isThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).A peptide derived from a protective protein in your stomach.
How it worksTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
Commonly reportedAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
Studied rangeResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.Research range: 200–500 mcg. Studied in research — not a recommendation.
How oftenWeeklyOnce or twice daily
Half-life~6 days (measured in early trials in people)~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
RouteSubQ injectionSubQ injection, IM injection, Oral (less studied)
Typical runPhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
EvidenceEstablished: clinical trials or FDA-approved use existsEmerging: primarily preclinical / limited human data
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal painNausea (rare), injection site irritation, vivid dreams, dizziness

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide or BPC-157? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Retatrutide

  • Day 1–28 · 2 mg Triple-agonist is kicking in
  • Day 29–84 · 4 mg Dose-response steepens
  • Day 60+ · 9 mg Watch for dysesthesia at higher doses
  • Day 84+ This is a maintenance medication, not a course
  • Day 85–168 · 8 mg Higher steps: strong satiety
  • Day 169–336 No plateau yet at week 48
  • Day 337–476 Phase 3 territory: the headline numbers

Every card for retatrutide, with its sources

BPC-157

  • Day 1–7 Week one: early hints, for some
  • Day 7–14 Pain often starts to ease
  • Day 14–21 Pain often eases by week three
  • Day 21–28 Many report a calmer gut
  • Day 28–42 The slower part of repair
  • Day 42–56 Six weeks in: taking stock
  • Day 84+ Past week 12, the data runs thin

Every card for BPC-157, with its sources

Together or one or the other

Retatrutide and BPC-157 are a common stack: retatrutide lists BPC-157 among its common stacks.

Community · Retatrutide

Why people add BPC-157 to Reta

Titrating up on Reta can be rough on the gut — especially the later transitions — and BPC-157 is added to ease it. Commonly reported: smoother step-ups with fewer GI side effects. One of the most common Reta pairings.

Questions people ask

How long do retatrutide and BPC-157 last?

The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes).

How often are retatrutide and BPC-157 taken?

Retatrutide: weekly. Route: SubQ injection. BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied).

How are retatrutide and BPC-157 dosed in research?

The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for BPC-157 is 200–500 mcg. Studied in research — not a recommendation.

What are the common side effects of retatrutide and BPC-157?

For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For BPC-157: nausea (rare), injection site irritation, vivid dreams, dizziness.

Are retatrutide and BPC-157 taken together?

Retatrutide and BPC-157 are a common stack: retatrutide lists BPC-157 among its common stacks. Titrating up on Reta can be rough on the gut — especially the later transitions — and BPC-157 is added to ease it. Commonly reported: smoother step-ups with fewer GI side effects. One of the most common Reta pairings.

Each one in full

Track it in the app

PepVault for iPhone

Taking retatrutide or BPC-157? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo